PRODUCT LITERATURE

Benefit: Risk Profle of Budesonide in Obstructive Airways Disease

---

Airway infammation is a major contributing factor in both asthma and chronic obstructive pulmonary disease (COPD) and
represents an important target for treatment. Inhaled corticosteroids (ICS) as monotherapy or in combination therapy with
long-acting β2-agonists or long-acting muscarinic antagonists are used extensively in the treatment of asthma and COPD.
The development of ICS for their anti-infammatory properties progressed through eforts to increase topical potency and
minimise systemic potency and through advances in inhaled delivery technology. Budesonide is a potent, non-halogenated
ICS that was developed in the early 1970s and is now one of the most widely used lung medicines worldwide. Inhaled budesonide’s physiochemical and pharmacokinetic/pharmacodynamic properties allow it to reach a rapid and high airway efcacy
due to its more balanced relationship between water solubility and lipophilicit

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Budesma
Budesonide
Obstructive Airways Disease

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment